BIO CEO & Investor Conference February 15 th , 2011 BIO / BioMedTracker Clinical Trial Success Rates Study Michael Hay, Senior Biotechnology Analyst, Sagient Research Systems Jesse Rosenthal, Senior Biotechnology Analyst, Sagient Research Systems David Thomas, Director, Industry Research & Analysis, Biotechnology Industry Organization (BIO) John Craighead, Ph.D., Managing Director, Investor Relations & Business Development, BIO
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
BIO CEO & Investor ConferenceFebruary 15th, 2011
BIO / BioMedTrackerClinical Trial Success Rates Study
Michael Hay, Senior Biotechnology Analyst, SagientResearch Systems
Jesse Rosenthal, Senior Biotechnology Analyst, SagientResearch Systems
David Thomas, Director, Industry Research & Analysis, Biotechnology Industry Organization (BIO)
John Craighead, Ph.D., Managing Director, Investor Relations & Business Development, BIO
MOST RECENT STUDIES
• 1,738 drugs(Only Lead indications)
• Must have entered into a Phase I 1993-2004
• Developed by the 50 largest Pharmas
TUFTS 2010*
• 4,275 drugs• 7,300 indications
(All indications)
• Any Phase during Oct 2003- Dec 2010
• All companies, Biotechs + Pharma including Private
BioMedTracker 2011
* DiMasi, et al. Nature Clinical Pharmacology and Toxicology, May 2010
21%19%
9%
14.5%
3.2%
Tufts '03 BMT Secondary Indications
OVERALL SUCCESS RATES
Tufts ’03Lead
Indications
BMTAll
Indications
BMTLead
Indications
BMTSecondaryIndications
21%19%
9%
14.7%
3.3%
Tufts '03 Tufts '10 BMT Lead Non-LeadTufts ’10Lead
Indications
*
* DiMasi, et al. Nature Clinical Pharmacology and Toxicology, May 2010
Panelists:• Ted Buckley, PhD, Chief Economist, Bloomberg• Lawrence T. Friedhoff, MD, PhD, FACP, CEO, Pharmaceutical Special Projects Group, LLC • Michael Hay, Senior Biotechnology Analyst, Sagient Research Systems• David Thomas, Director, Industry Research & Analysis, BIO